Medicovestor Selected as Finalist to Present Its First-in-Class ADC Platforms at JP Morgan Asset Management: Life Sciences Innovation Summit
Unlike current ADCs, Medicovestor's groundbreaking first-in-class ADC platforms prioritize the "A" (antibody) over the "DC" (drug conjugate), harnessing the intrinsic antitumor activities of the backbone antibody.
- Unlike current ADCs, Medicovestor's groundbreaking first-in-class ADC platforms prioritize the "A" (antibody) over the "DC" (drug conjugate), harnessing the intrinsic antitumor activities of the backbone antibody.
- "We are thrilled to be selected as a finalist for this prestigious summit," said Dr. Seah Lim , Founder and CEO of Medicovestor.
- The Life Sciences Innovation Summit, hosted by JP Morgan Asset Management, serves as a prestigious platform for leading innovators, investors, and industry experts to explore cutting-edge advancements in healthcare and life sciences.
- During the summit, Medicovestor aims to share insights into its ADC platform development, preclinical progress, and future prospects.